Form 4: Pulse Biosciences Executive Levinson Acquires Shares and Warrants Through Rights Offering

Mitchell E. Levinson, Chief Strategy Officer of Pulse Biosciences, acquired common stock and warrants through the company's rights offering on September 24, 2024.

Summary

• Mitchell E. Levinson, Chief Strategy Officer of Pulse Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On September 24, 2024, Levinson acquired 3,000 shares of common stock at $11 per share through the exercise of subscription rights in a rights offering.
• He also acquired warrants to purchase 1,500 shares of common stock at an exercise price of $11 per share, expiring on July 3, 2029.
• Levinson's spouse and immediate family members also acquired shares and warrants through the rights offering.
• The rights offering involved purchasing units at $10 each, with each unit containing one share of common stock and two warrants to purchase one-half share each.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. Executive participation in a rights offering is generally a good sign, indicating confidence in the company's prospects. However, it's a routine filing related to a previously announced event.

Positives

• Executive participation in the rights offering demonstrates confidence in the company's future.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the warrants and rights offering.

Industry Context

Rights offerings are a common method for companies, particularly smaller ones, to raise capital from existing shareholders. Executive participation is often viewed positively.

Stakeholder Impact

• The rights offering provides existing shareholders with the opportunity to increase their stake in the company.
• Executive participation may boost investor confidence.

Key Dates